Women’s health · Menopause · Reading clinical evidence
Is the Dong Quai research in Estella ads a trial of this jar?
No. Hirata 1997 (PMID 9418683) tested dong quai root alone at about 4.5 g/day for 24 weeks in 71 women.
It was no better than placebo for hot flashes, and it is not an RCT of this multi-extract jar.
Red flag symptoms that mean stopping the ad research and seeing a clinician
If any of the following apply, see a clinician so the cause can be identified first.
These findings need diagnosis, not a comparison of supplement formulas.
- Any vaginal bleeding after menopause, even light spotting, always requires evaluation of the endometrium.
- A new breast or underarm lump, skin dimpling, or one-sided nipple discharge or bleeding.
- Unusual bleeding or easy bruising, particularly if you take warfarin or an antiplatelet medicine.
- One-sided leg swelling with calf tenderness, or sudden breathlessness with chest pain on inspiration.
- Sudden neurological symptoms such as facial droop, one-sided weakness, slurred speech, or sudden visual loss.
- Yellow eyes or skin, or severe right upper abdominal pain after starting a new product.
- Widespread hives, swelling of the face or tongue, or difficulty breathing, which suggests a severe allergic reaction and needs emergency care immediately.
Hirata 1997 tested dong quai root alone, and the result was no better than placebo
Direct answer: the trial most often cited when dong quai and menopause are discussed
is the randomised, double-blind, placebo-controlled study by Hirata and colleagues published in 1997.
The record is available at
PubMed PMID 9418683.
Four features of what that trial actually did are worth remembering.
First, the participants were 71 postmenopausal women.
Second, what they received was dong quai root, Angelica sinensis, as a single ingredient,
at approximately 4.5 grams per day.
Third, follow-up ran for 24 weeks, long enough to see a trend.
Fourth, there was a placebo comparison group, which is essential in menopausal symptoms
because the placebo response is substantial.
The findings answered two questions at once. The first question was whether it helped symptoms:
the herb group did no better than the placebo group at reducing hot flashes.
The second question was whether it had estrogen-like activity:
no estrogen-like change was found in either endometrial thickness or vaginal cell maturation.
- Population: 71 postmenopausal women
- Intervention: dong quai root alone, approximately 4.5 g per day
- Duration: 24 weeks, against placebo
- Symptom result: no better than placebo for hot flashes
- Mechanistic result: no estrogen-like change in endometrium or vaginal maturation
A single-ingredient trial is not evidence for a multi-extract finished formula
Direct answer: methodologically, a blend is a new product that has to be tested in its own right,
so the Hirata 1997 result cannot be borrowed to support a jar containing many ingredients.
The reason lies in every variable that changes.
Moving from a single root to a blend changes the ingredients themselves, the proportion of each,
the amount per serving, the extraction method and the concentration of active constituents,
the dosage form and therefore absorption, and the interactions between components,
which may add to or cancel each other. When all of that changes, the outcome can change in either direction,
better or worse. That is why transferring a claim across products is not accepted.
The
NCCIH
concludes that there is little research on dong quai for menopause.
When the single-ingredient evidence base is already thin,
extending it to stand in for a blend leaves nothing underneath.
So the question to put to a seller is short: is there research on this formula itself, and where was it published?
Steps for checking whether a cited study matches the product actually being sold.
“Free of estrogenic activity” answers neither the outcome question nor the cancer question
Direct answer: that phrase is mechanistic information. It says only that a substance did not act
through the estrogen receptor in what was measured. It does not say the product treats symptoms,
and it does not say the product carries no cancer risk.
Those three questions require three different bodies of data.
Why it is not an answer about effectiveness
Vasomotor symptoms fall when the thermoneutral zone in the hypothalamus widens again,
which is something estrogen can do. If a formula declares it has no estrogen-like activity,
it is declaring that it does not act through that pathway,
so it would have to explain an alternative mechanism and supply clinical data instead.
Using a single statement as both the reason it is safe and the reason it works is a self-contradicting claim.
Why it is not an answer about cancer risk
A cancer question is answered by following groups of patients for years
and comparing rates of new disease or recurrence between those exposed and not exposed.
Finding no estrogen-like activity in a particular measurement is only the start of a safety hypothesis,
not a conclusion. Anyone with a history of hormone-sensitive cancer still needs their treating clinician
to review the full ingredient list before starting.
Why patents and awards do not count as clinical evidence
A patent certifies that a process or composition is novel and inventive under intellectual property law.
It does not certify outcomes in people. A trade-show award is recognition in a commercial setting,
not an assessment by clinical experts.
Both therefore sit in a different category from a published, checkable randomised controlled trial.
The caution to know first: dong quai may interact with warfarin
Direct answer: the NCCIH states explicitly that dong quai may interact with warfarin,
an anticoagulant whose INR has to be held inside a narrow range.
The consequence is an unstable INR that leads either to easy bleeding or back toward clot risk,
and users often do not notice until symptoms appear.
- If you take warfarin or another anticoagulant: ask your clinician and pharmacist before starting,
and if combined use is approved, expect more frequent INR checks at the start. - If you take an antiplatelet medicine: disclose the product name and full ingredient list,
because bleeding risk may increase. - If you have surgery, a procedure, or a dental extraction coming up: tell your care team in advance,
as you may be asked to stop beforehand. - If you have a history of hormone-sensitive cancer: have your treating clinician review
the full ingredient list before you start. - If you are pregnant or breastfeeding: do not self-prescribe botanicals of this kind without advice.
nosebleeds that will not stop, heavy gum bleeding, black tarry stools, blood in the urine,
or a sudden severe headache.
Want to know where your symptoms should be assessed first?
Review your severity level and receive personalized guidance from our Advisory team.
Take the free menopause symptom assessment
Women’s health category:
Menopause and women’s health hub
Claim audit table: what is cited compared with what was actually tested
Direct answer: most claims in this advertising are formulation facts, intellectual property facts,
or mechanistic facts, rather than trial results for the finished product being sold.
The table uses drug classes and generic names only, so evidence levels line up directly.
| What is cited | What was actually tested | Reported result | Can it be claimed for the jar on sale? |
|---|---|---|---|
| Dong quai (Angelica sinensis) — Hirata 1997 (PMID 9418683) | Dong quai root alone, approximately 4.5 g per day for 24 weeks, in 71 postmenopausal women against placebo | No better than placebo for hot flashes, and no estrogen-like change in endometrial thickness or vaginal cell maturation | No. It is evidence about a single ingredient, not about a blend |
| The multi-extract finished formula of the supplement on sale | No published, checkable randomised placebo-controlled trial of the same finished formula has been identified | No placebo-comparison outcome data available to assess | No, because there is no trial result for that formula to cite |
| A foreign patent | Novelty and inventiveness of a process or composition under intellectual property law | A grant of rights, not a clinical outcome in people | Only as a patent fact, never as an effectiveness claim |
| Trade-show awards and the number of extracts from several countries | Commercial recognition and raw material sourcing | Not an assessment by clinical experts, and no outcome measures reported | No, not for effectiveness or safety |
| The phrase free of estrogen-like activity | A mechanistic measurement of whether a substance binds the estrogen receptor in what was measured | Mechanistic information only, not symptom outcomes and not long-term follow-up | Only as a mechanistic statement, and it argues against the effectiveness claim |
| The phrase no cancer risk | Would require multi-year patient follow-up comparing rates of new disease or recurrence | No data of that kind appears in the advertising material | No, and it is not oncology clearance |
| MHT (estradiol or conjugated estrogens, plus a progestogen if the uterus is present) | Extensive trials and systematic reviews, summarised in the 2022 NAMS position statement | Most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause, with a favourable benefit-risk balance for people under 60 or within 10 years of menopause onset without contraindications | No. It is evidence about a medicine, not about a dietary supplement |
| Non-hormonal options (SSRIs and SNRIs such as paroxetine and venlafaxine, gabapentin, the NK3 receptor antagonist fezolinetant) | Clinical trials in people with vasomotor symptoms who are not using hormones | Moderate reductions in symptom frequency or severity, with systematically monitored side-effect data | No. These require prescription and clinician follow-up |
Scientific mechanism: why single-ingredient results cannot be lent to a blend
By
Asst. Prof. Dr. Norawit Raatpiboon
(ผศ.ดร.นรวิชญ์ ราษฎร์พิบูลย์):
vasomotor symptoms arise when the thermoneutral zone in the hypothalamus narrows
because estradiol is low and fluctuating. Effective treatment therefore has to intervene
in that thermoregulatory circuit, either by supplying estrogen
or by modulating signalling in the KNDy neurons, which is the target of NK3 receptor antagonists
such as fezolinetant. The Hirata 1997 trial already answered that dong quai root alone
showed no estrogen-like effect at either the endometrium or vaginal epithelium,
which is consistent with the absence of any benefit over placebo.
Once the product becomes a blend, its whole pharmacology changes.
Each extract carries a different class of active constituents at different concentrations
depending on the extraction method, and they may compete at the cytochrome P450 enzymes
that metabolise many medicines. The combined effect is therefore not a linear sum of the parts
and cannot be predicted from single-ingredient studies.
That is the mechanistic reason a blend needs a trial of its own.
Two practical conclusions follow for readers.
First, seeing a study named in an advertisement does not mean the product was tested;
check what the study tested, in whom, and for how long.
Second, if symptoms are disrupting your life, the faster route is to bring your symptom data
to a gynaecologist to assess whether MHT or a non-hormonal option would help.
Frequently asked questions
Is the dong quai study cited in the advertising a trial of this jar?
No. The study most often cited in this context is the trial by Hirata and colleagues published in 1997
(PMID 9418683), which tested dong quai root, Angelica sinensis, on its own against placebo.
That trial did not test the multi-extract finished formula of any supplement on the market,
so its results cannot be transferred to the jar being sold.
If an advertisement wants to claim results for its own formula,
it needs a trial that tested the same formula at the same dose in a menopausal population
and reported vasomotor symptom outcomes explicitly.
What did Hirata 1997 test, and what was the result?
It was a randomised, double-blind, placebo-controlled trial in 71 postmenopausal women,
giving approximately 4.5 grams of dong quai root per day for 24 weeks.
The result was that the herb group did no better than the placebo group at reducing hot flashes,
and no estrogen-like changes were found in either endometrial thickness or vaginal cell maturation.
The trial therefore answered two questions at once: no benefit was demonstrated for symptoms,
and no signal of estrogen-like activity was demonstrated either.
If dong quai alone did not work, could a 15-extract blend work better?
Nobody can answer that from the data that exists, because adding extracts does not add evidence.
Methodologically, a blend is a new product that has to be tested in its own right,
since the proportions, the dose, the extraction method,
and the interactions between components all differ from a single-ingredient study.
Using the result of one single-ingredient trial to support a blend is a claim transferred across products.
The NCCIH notes there is little research on dong quai for menopause at all,
which leaves claims about blends with even less to stand on.
Does free of estrogenic activity mean the product is safe from cancer?
It does not mean that. The absence of estrogen-like activity in a particular measurement
is mechanistic information, not long-term patient follow-up showing no effect
on the development or recurrence of hormone-sensitive cancer.
A cancer risk question is answered by following groups of patients for years and comparing disease rates.
In addition, the same statement works against the effectiveness claim,
because if a formula truly has no estrogen-like activity
then it has no mechanism to replace what hormone therapy does to reduce vasomotor symptoms.
Can a foreign patent or a trade-show award substitute for clinical research?
No. A patent certifies that a process or composition is novel and inventive enough
under intellectual property law; it does not certify that the product reduces menopausal symptoms in people.
A trade-show award is recognition in a commercial setting, not an assessment by clinical experts.
Answering the effectiveness question requires a published, checkable randomised controlled trial
that states the number of participants, the duration, the dose used, and the outcome measures.
What cautions should I know about dong quai before taking it?
The caution the NCCIH states explicitly is that dong quai may interact with warfarin, an anticoagulant.
The consequence is an unstable INR that can lead either to easy bleeding or to clot formation.
Anyone taking an anticoagulant or an antiplatelet medicine,
or facing surgery or a dental extraction, should ask their clinician and pharmacist first.
Anyone with a history of hormone-sensitive cancer should have their treating clinician
review the full ingredient list beforehand, and should report any easy bruising,
nosebleeds that will not stop, or black stools straight away.
If I still want to try a supplement, what should I check before deciding?
Check four things before you pay.
First, read the ingredient panel and the actual amount per serving,
not only the text on the advertising image.
Second, ask directly for research on that specific formula,
requesting the journal, the year, the number of participants, and the outcome measures used.
Third, check whether you have any red flag symptom that needs evaluation first,
particularly vaginal bleeding after menopause.
Fourth, tell the clinician and pharmacist who manage your regular medicines,
especially if you take warfarin, an antiplatelet agent, or treatment for hormone-sensitive cancer.
Read next in this cluster
Read the first layer to understand the product category and the one-month timeframe,
and the second layer to learn who must never swap prescribed hormone therapy for a supplement alone.
Academic citations (E-E-A-T)
-
Hirata JD et al. 1997 — Does dong quai have estrogenic effects in postmenopausal women? (PMID 9418683)
— randomised, double-blind, placebo-controlled trial, n=71, approximately 4.5 g per day of dong quai root
for 24 weeks; no better than placebo for hot flashes,
and no estrogen-like change in endometrium or vaginal maturation. -
NCCIH — Menopausal Symptoms: In Depth
— notes there is little research on dong quai for menopause and that it may interact with warfarin. -
NAMS 2022 hormone therapy position statement (PMID 35797481)
— MHT is the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause,
with a favourable benefit-risk balance for people under 60 or within 10 years of menopause onset
and without contraindications. -
National Institute on Aging — What Is Menopause?
— defines menopause as the point twelve months after the final menstrual period. -
ACOG — Hormone Therapy FAQ
— patient-facing information on shared decision-making about hormone therapy. -
dr9ohm.com — Perimenopause symptoms guide (40+)
— background on the hormonal mechanisms of the transition.
Author and content reviewer:
Asst. Prof. Dr. Norawit Raatpiboon
(ผศ.ดร.นรวิชญ์ ราษฎร์พิบูลย์)
Medical disclaimer
This article is educational information about reading and checking the scientific claims
that appear in dietary supplement advertising. It is not a diagnosis, not a prescription,
and not an individual assessment of any product.
Naming a dietary supplement here describes its regulatory category and how to check its claims only;
it is neither an endorsement nor an allegation that any product does or does not treat disease.
Starting or stopping a dietary supplement while taking regular medicines,
especially warfarin, an antiplatelet agent, or treatment for hormone-sensitive cancer,
requires advice from your clinician and pharmacist first.
Seek care immediately for vaginal bleeding after menopause, a new breast lump,
unusual bleeding, or a severe allergic reaction.
If you have thoughts of self-harm, contact your local emergency number or crisis line right away;
in Thailand the mental health hotline 1323 is available 24 hours a day.